Q2 FY2026 EarningsQ2 FY26 results significantly beat consensus across all major metrics, driven by an 88.9% YoY surge in Pharma revenue and strong margin expansion. Revenue reached $28.3M, exceeding expectations by 7.2%, while GAAP EPS of $0.11 beat the $0.06 consensus by 83.3%. Management subsequently raised full-year FY26 revenue and Adjusted EBITDA guidance above previous market expectations.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Paysign(PAYS) the Revenue is 28.25 M (+48.08%), Beat estimate;the EBIT is 6.021 M (+318.8%), Beat estimate;the EPS is 0.11 (+450%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.03B48.08%
0.03B38.16%
+0.00B9.92%
EBITExceed expectations
0.01B318.81%
0.00B168.86%
+0.00B149.95%
EPSExceed expectations
0.11450.00%
0.06200.00%
+0.0500250.00%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf